We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vanda Pharmaceuticals Inc | NASDAQ:VNDA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.40% | 4.99 | 4.92 | 5.14 | 5.08 | 4.87 | 5.00 | 1,384,022 | 01:00:00 |
From Nov 2023 to May 2024
By Colin Kellaher
Shares of Vanda Pharmaceuticals rose sharply in premarket trading Tuesday after the biopharmaceutical company said the U.S. Food and Drug Administration accepted its application seeking approval of tradipitant for the treatment of symptoms of the digestive condition gastroparesis.
After the closing bell Monday, Vanda said the FDA set a target action date of Sept. 18, 2024, for the application.
Vanda said an FDA green light would make tradipitant the first novel drug approved by the agency in more than four decades for gastroparesis, which prevents the stomach from emptying properly.
Vanda shares, which closed Monday at $3.85, were recently up nearly 19% to $4.57 in light premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 05, 2023 06:08 ET (11:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Vanda Pharmaceuticals Chart |
1 Month Vanda Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
